Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

Eli Lilly's shares are up well over 50 percent since the beginning of the year. More on weight loss drugs: Patients Taking ...

We saw that happen with Eli ... and development charges the company incurred in Q3 that were primarily related to its acquisition of Morphic Holding. Without this acquisition, Lilly almost ...

Eli Lilly and Company (NYSE:LLY) is engaged in discovering, developing, and marketing human pharmaceuticals worldwide. Eli Lilly and Company (NYSE:LLY) saw significant attention because of its ...

Why did Eli Lilly’s Mounjaro and Zepbound sales miss ... reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

However, Eli Lilly continued to develop GLP-1 drugs, getting Trulicity, which is used to treat type 2 diabetes, approved in 2014. By 2018, Trulicity would become Eli Lilly's top-selling drug ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE:LLY) for a little while now. My first article about the company, published in ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

The U.S. Food and Drug Administration has recalled over 7,000 bottles of the antidepressant duloxetine, which is commonly sold under the name Cymbalta. According to the FDA, the drug was recalled ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of analyst coverage. GLP-1 adoption has fueled Lilly’s ...

Editas Medicine and Genevant Sciences announced plans to collaborate on development of novel mRNA-LNP gene editing ... MangoRx refuted claims made by Eli Lilly regarding the sale of compounded ...

Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion.